Metastatic Colorectal Cancer - Pipeline Review, H1 2016

Description: Metastatic Colorectal Cancer - Pipeline Review, H1 2016

Summary

‘Metastatic Colorectal Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
- The report reviews pipeline therapeutics for Metastatic Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Colorectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction

Metastatic Colorectal Cancer Overview

Therapeutics Development

Metastatic Colorectal Cancer - Therapeutics under Development by Companies

Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes

Metastatic Colorectal Cancer - Pipeline Products Glance

Metastatic Colorectal Cancer - Products under Development by Companies

Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes

Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development

Metastatic Colorectal Cancer - Therapeutics Assessment

Drug Profiles

Metastatic Colorectal Cancer - Recent Pipeline Updates

Metastatic Colorectal Cancer - Dormant Projects

Metastatic Colorectal Cancer - Discontinued Products

Metastatic Colorectal Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Metastatic Colorectal Cancer, H1 2016

Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2016
Metastatic Colorectal Cancer - Pipeline by AB Science SA, H1 2016
Metastatic Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by AdvanCen Laboratories, LLC, H1 2016
Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016
Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
Metastatic Colorectal Cancer - Pipeline by Baxalta Incorporated, H1 2016
Metastatic Colorectal Cancer - Pipeline by Bayer AG, H1 2016
Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Bionovis SA, H1 2016
Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016
Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016
Metastatic Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2016
Metastatic Colorectal Cancer - Pipeline by EnGeneIC Ltd, H1 2016
Metastatic Colorectal Cancer - Pipeline by Etubics Corporation, H1 2016
Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H1 2016
Metastatic Colorectal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Hetero Drugs Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Ignyta, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Immatics Biotechnologies GmbH, H1 2016
Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Mabion SA, H1 2016
Metastatic Colorectal Cancer - Pipeline by Mabtech Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by mAbxience S.A., H1 2016
Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by MedImmune, LLC, H1 2016
Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H1 2016
Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Merus B.V., H1 2016
Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Mologen AG, H1 2016
Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Mycenax Biotech Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Natco Pharma Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H1 2016
Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Novartis AG, H1 2016
Metastatic Colorectal Cancer - Pipeline by OBI Pharma, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Oncobiologics, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Pharma Mar, S.A., H1 2016
Metastatic Colorectal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Precision Biologics, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016
Metastatic Colorectal Cancer - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016
Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H1 2016
Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016
Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016
Metastatic Colorectal Cancer - Pipeline by Tocagen Inc., H1 2016
Metastatic Colorectal Cancer - Pipeline by Vaximm AG, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Metastatic Colorectal Cancer - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3759028/
Office Code: SCPLXXKXD

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: _________________________________________
Email Address: * ____________________________________________
Job Title: _______________________________________________
Organisation: ____________________________________________
Address: ________________________________________________
City: ___________________________________________________
Postal / Zip Code: _________________________________________
Country: ________________________________________________
Phone Number: ___________________________________________
Fax Number: _____________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World